Media Coverage

Quest Diagnostics and Elevance Health are broadening their partnership into four more states with the goal of making it easier for patients to access in-network laboratory services. Beginning Jan. 1, Quest's service will be available in-network in four additional states: Colorado, Georgia, Nevada and Virginia. This includes routine lab testing, advanced diagnostics and Quest's network of pathologists, according to an announcement.

Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus. WHY IT'S IMPORTANT: The spread of bird flu among dairy herds and infections of 27 people this year have alarmed some public health experts.

Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests. Demand for diagnostic checkups has grown in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.

Quest Diagnostics has launched a self-collection option for testing for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium. The test uses Hologic's FDA-cleared Aptima Multi-test swab for patient-collected vaginal specimens and can be used by patients to self-collect specimens in Quest patient service centers or in traditional clinical settings like a doctor's office.

Quest Diagnostics has completed its purchase of select laboratory assets from Columbus-based OhioHealth. The two parties signed an agreement for the assets in early July, with financial terms from the transaction not shared. The purchase aims to expand access to cost-effective laboratory services in Ohio.

Quest Diagnostics has announced seven acquisitions this year, including its recent purchase of select lab assets from Minneapolis-based Allina Health. Slated to close later this year are deals with OhioHealth in Columbus and University Hospitals in Cleveland. "In order to grow our business, we want to be able to do more work with hospitals that are doing outpatient or outreach lab tests ordered by independent physicians outside of their facility,” said Jim Davis, president and CEO of Quest Diagnostics.

Type 2 diabetes is a chronic condition where the body either doesn’t produce enough insulin or doesn’t use it effectively, causing high blood sugar levels. Insulin is crucial for helping the body convert glucose into energy. When insulin doesn’t work properly, glucose accumulates in the bloodstream, leading to increased blood sugar. Over time, this can result in serious complications such as organ damage and a higher risk of heart attack or stroke. “Diabetes can affect every organ system,” says Sanjay Dixit, MD, medical director of cardiometabolic endocrine and wellness clinical solutions at Quest Diagnostics. “Early detection and management of type 2 diabetes is crucial.”

Quest Diagnostics on Monday completed its acquisition of select lab assets of Allina Health in a deal that builds on the industry trend of independent companies taking over the outpatient lab operations of health systems.

Quest Diagnostics and Sentara Health Plans said Wednesday that they have entered into a multi-year strategic collaboration. Under the agreement, Quest will, at the beginning of 2025, become the exclusive independent national laboratory provider of clinical laboratory and anatomic pathology services for Sentara members in Florida and Virginia.

Adherence to guideline-based laboratory testing and treatment of chlamydia and gonorrhea in pregnant women has been found to be suboptimal in the United States, indicating the potential for negative effects on newborn and maternal health, according to a recently published study in the Journal of Lower Genital Tract Disease. Researchers from Quest Diagnostics and the University of Alabama sought to evaluate adherence to national recommendations for chlamydia and gonorrhea testing during pregnancy. This evaluation also included tests for persistence/potential reinfection at time of delivery and cure/clearance.